To determine the influence of hemoglobinopathy on growth and development, we examined the height, weight, and sexual maturation of 2115 patients 2 to 25 years old who had homozygous sickle-cell disease (SS), SC disease (SC), sickle beta+ thalassemia (S beta+), or sickle beta O thalassemia (S beta O). Using regression analysis of these cross-sectional data to generate growth and maturation curves for each hemoglobinopathy, we found that the curves for all hemoglobinopathy groups were significantly different from published norms for black subjects (P less than 0.001), and that subjects with SS and S beta O were consistently smaller and less sexually developed than those with SC and S beta+ (P less than 0.001). For both sexes and all hemoglobinopathies, low weight was more pronounced than short height and was most apparent in subjects over the age of seven. The median age of the female subjects who had attained at least Tanner Stage V was 17.3 years for those with SS, 17.2 years for S beta O, 16.0 years for SC, and 16.5 years for S beta+; among male subjects the corresponding values were 17.6, 18.8, 16.6, and 16.6 years. Discriminant analysis of menarche status, weight, age, and hemoglobinopathy revealed that the influences of age and weight on menarche were similar regardless of hemoglobinopathy. This relationship suggests a constitutional rather than a primary endocrinologic cause of sexual immaturity in patients with hemoglobinopathies.
This article has been cited by other articles:
Berthaut, I., Guignedoux, G., Kirsch-Noir, F., de Larouziere, V., Ravel, C., Bachir, D., Galacteros, F., Ancel, P.-Y., Kunstmann, J.-M., Levy, L., Jouannet, P., Girot, R., Mandelbaum, J.
(2008). Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. haematol
93: 988-993
[Abstract][Full Text]
Buison, A. M., Kawchak, D. A., Schall, J. I., Ohene-Frempong, K., Stallings, V. A., Leonard, M. B., Zemel, B. S.
(2005). Bone Area and Bone Mineral Content Deficits in Children With Sickle Cell Disease. Pediatrics
116: 943-949
[Abstract][Full Text]
Hankins, J. S., Ware, R. E., Rogers, Z. R., Wynn, L. W., Lane, P. A., Scott, J. P., Wang, W. C.
(2005). Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood
106: 2269-2275
[Abstract][Full Text]
Steen, R. G., Emudianughe, T., Hunte, M., Glass, J., Wu, S., Xiong, X., Reddick, W. E.
(2005). Brain Volume in Pediatric Patients with Sickle Cell Disease: Evidence of Volumetric Growth Delay?. Am. J. Neuroradiol.
26: 455-462
[Abstract][Full Text]
Zimmerman, S. A., Schultz, W. H., Davis, J. S., Pickens, C. V., Mortier, N. A., Howard, T. A., Ware, R. E.
(2004). Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood
103: 2039-2045
[Abstract][Full Text]
Barden, E. M, Kawchak, D. A, Ohene-Frempong, K., Stallings, V. A, Zemel, B. S
(2002). Body composition in children with sickle cell disease. Am. J. Clin. Nutr.
76: 218-225
[Abstract][Full Text]
Singhal, A., Parker, S., Linsell, L., Serjeant, G.
(2002). Energy intake and resting metabolic rate in preschool Jamaican children with homozygous sickle cell disease. Am. J. Clin. Nutr.
75: 1093-1097
[Abstract][Full Text]
Zemel, B. S, Kawchak, D. A, Fung, E. B, Ohene-Frempong, K., Stallings, V. A
(2002). Effect of zinc supplementation on growth and body composition in children with sickle cell disease. Am. J. Clin. Nutr.
75: 300-307
[Abstract][Full Text]
Ivascu, N. S., Sarnaik, S., McCrae, J., Whitten-Shurney, W., Thomas, R., Bond, S.
(2001). Characterization of Pica Prevalence Among Patients With Sickle Cell Disease. Arch Pediatr Adolesc Med
155: 1243-1247
[Abstract][Full Text]
Serjeant, G R, Singhal, A, Hambleton, I R
(2001). Sickle cell disease and age at menarche in Jamaican girls: observations from a cohort study. Arch. Dis. Child.
85: 375-378
[Abstract][Full Text]
Buchowski, M. S., Simmons, L. A., Chen, K. Y., Flakoll, P. J., Mellen, B. G., Turner, E. A.
(2000). Plasma Leptin Association with Body Composition and Energy Expenditure in Sickle Cell Disease. J. Am. Coll. Nutr.
19: 228-236
[Abstract][Full Text]
Walters, M. C., Storb, R., Patience, M., Leisenring, W., Taylor, T., Sanders, J. E., Buchanan, G. E., Rogers, Z. R., Dinndorf, P., Davies, S. C., Roberts, I. A. G., Dickerhoff, R., Yeager, A. M., Hsu, L., Kurtzberg, J., Ohene-Frempong, K., Bunin, N., Bernaudin, F., Wong, W.-Y., Scott, J. P., Margolis, D., Vichinsky, E., Wall, D. A., Wayne, A. S., Pegelow, C., Redding-Lallinger, R., Wiley, J., Klemperer, M., Mentzer, W. C., Smith, F. O., Sullivan, K. M.
(2000). Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Blood
95: 1918-1924
[Abstract][Full Text]
Thomas, P W, Singhal, A, Hemmings-Kelly, M, Serjeant, G R
(2000). Height and weight reference curves for homozygous sickle cell disease. Arch. Dis. Child.
82: 204-208
[Abstract][Full Text]
Rolfs, A., Muhlschlegel, F., Jansen-Rosseck, R., Martins, A. R., Bedaque, E. A., Tamburus, W. M., Pedretti, L., Schulte, G., Feldmeier, H., Kremsner, P.
(1995). Clinical and Immunologic Follow-up Study of Patients with Neurocysticercosis After Treatment with Praziquantel. Neurology
45: 532-538
[Abstract][Full Text]
Powars, D. R., Brown, M.
(1990). Sickle Cell Disease: Summer Camp Experience of a 22-year Community-supported Program. CLIN PEDIATR
29: 81-85
[Abstract]
Finan, A. C., Elmer, M. A., Sasanow, S. R., McKinney, S., Russell, M. O., Gill, F. M.
(1988). Nutritional Factors and Growth in Children With Sickle Cell Disease. Arch Pediatr Adolesc Med
142: 237-240
[Abstract]
Scott, R. B.
(1985). Advances in the Treatment of Sickle Cell Disease in Children. Arch Pediatr Adolesc Med
139: 1219-1222
[Abstract]
Johnson, C. S.
(1985). Sickle Cell Anemia. JAMA
254: 1958-1963
[Abstract]
Hankins, J. S., Ware, R. E., Rogers, Z. R., Wynn, L. W., Lane, P. A., Scott, J. P., Wang, W. C.
(2005). Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood
106: 2269-2275
[Abstract][Full Text]
Previous
